COCP
Cocrystal Pharma, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-4/100
Last price
1.11
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.11
Day high
1.13
Day low
1.10
Volume
28.50K
Market cap
$21.38M
P/E (TTM)
—
52W range
0.76 – 2.03
Trailing performance
Returnvs SPY
1W
-0.89%
-2.8%
1M
-1.77%
-2.9%
3M
+13.27%
+8.7%
6M
-24.49%
-42.7%
YTD
+13.27%
-1.0%
1Y
-8.26%
-24.7%
3Y
-40.64%
-122.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on COCP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
12.66M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 5, 26 | FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security |
BUY | 10.00K | $9.82K | Indirect |
| Aug 3, 26 | FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security |
BUY | 75.00K | $70.59K | Indirect |
| Feb 24, 26 | FROST PHILLIP MD ET AL Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 20.00K | $19.95K | Indirect |
| Feb 6, 26 | FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security |
BUY | 50.00K | $47.28K | Indirect |
| Dec 31, 25 | FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security |
BUY | 50.00K | $47.27K | Indirect |
| Dec 30, 25 | FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security |
BUY | 20.00K | $19.31K | Indirect |
| Dec 26, 25 | FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security |
BUY | 65.00K | $63.20K | Indirect |
| Nov 26, 25 | FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security |
BUY | 4.00K | $3.98K | Indirect |
| Nov 25, 25 | FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security |
BUY | 20.00K | $18.81K | Indirect |
| Oct 28, 25 | PFENNIGER RICHARD C JR Director |
STOCK | 20.00K | $0 | Direct |
| Oct 28, 25 | MARTIN JAMES J. CPA Chief Executive Officer |
STOCK | 3.60K | $4.14K | Direct |
| Oct 28, 25 | FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security |
STOCK | 359.71K | $413.67K | Indirect |
| Oct 28, 25 | HASSAN FRED Director |
STOCK | 359.71K | $413.67K | Direct |
| Oct 9, 24 | PFENNIGER RICHARD C JR Director |
STOCK | 8.07K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
FROST PHILLIP MD ET AL |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
HASSAN FRED |
Director | 1.38M | Stock Award(Grant) |
JAPOUR ANTHONY J M.D. |
Director | 14.92K | Stock Award(Grant) |
KORNBERG ROGER D |
Director | 67.88K | Stock Award(Grant) |
LEE SAM PH.D. |
Chief Executive Officer | 76.36K | Stock Award(Grant) |
MARTIN JAMES J. CPA |
Chief Executive Officer | 44.17K | Stock Award(Grant) |
PFENNIGER RICHARD C JR |
Director | 31.40K | Stock Award(Grant) |
RUBIN STEVEN DANIEL |
Director | 2.66M | Stock Award(Grant) |
Fundamentals
Market cap$21.38M
Enterprise value$20.55M
Revenue (TTM)$330.00K
Gross profit$-5.76M
EBITDA$-10.06M
Net income$-9.94M
EPS (TTM)$-0.76
Free cash flow$-4.32M
Total cash$2.17M
Total debt$1.34M
Book value / share$0.08
Shares outstanding19.26M
Float11.91M
Short % of float2.04%
Dividend yield0.00%
Beta (5Y)1.48
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.91
PEG ratio—
Price / sales—
Price / book14.61
EV / revenue62.29
EV / EBITDA-2.04
Gross margin0.00%
Operating margin-3032.38%
Profit margin0.00%
Return on equity-311.68%
Return on assets-96.07%
Debt / equity128.45
Current ratio1.24
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $5.05M | $12.54M | $15.17M | $12.39M | -59.7% |
| Selling, general & admin | $3.96M | $5.34M | $5.99M | $5.75M | -25.8% |
| Total operating expense | $9.02M | $17.88M | $21.16M | $18.14M | -49.6% |
| Operating income | -$9.02M | -$17.88M | -$21.16M | -$18.14M | +49.6% |
| Net interest income | $134.00K | $537.00K | $640.00K | -$2.00K | -75.0% |
| Pre-tax income | -$8.83M | -$17.50M | -$17.98M | -$38.84M | +49.5% |
| Net income | -$8.83M | -$17.50M | -$17.98M | -$38.84M | +49.5% |
| Net income to common | -$8.83M | -$17.50M | -$17.98M | -$38.84M | +49.5% |
| Basic EPS | -0.78 | -1.72 | -1.87 | -4.77 | +54.7% |
| Diluted EPS | -0.78 | -1.72 | -1.87 | -4.77 | +54.7% |
| EBIT | -$9.02M | -$17.88M | -$21.16M | -$18.14M | +49.6% |
| EBITDA | -$8.64M | -$17.43M | -$21.16M | -$17.75M | +50.4% |
| Basic shares | 11.29M | 10.17M | 9.65M | 8.14M | +11.0% |
| Diluted shares | 11.29M | 10.17M | 9.65M | 8.14M | +11.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.03M | $9.86M | $26.35M | $37.14M | — | -28.8% |
| Cash & short-term investments | $7.03M | $9.86M | $26.35M | $37.14M | — | -28.8% |
| Accounts receivable | — | — | — | — | $0 | — |
| Total current assets | $8.13M | $11.58M | $29.09M | $40.18M | — | -29.8% |
| Property, plant & equipment | $1.48M | $1.85M | $2.12M | $616.00K | — | -19.7% |
| Goodwill & intangibles | — | — | — | $0 | $19.09M | — |
| Total assets | $9.71M | $13.46M | $31.26M | $40.84M | — | -27.8% |
| Total current liabilities | $2.21M | $2.43M | $3.26M | $1.22M | — | -9.0% |
| Total debt | $1.50M | $1.81M | $1.85M | $297.00K | — | -16.7% |
| Total liabilities | $3.38M | $3.93M | $4.88M | $1.27M | — | -14.0% |
| Retained earnings | -$342.25M | -$333.42M | -$315.91M | -$297.93M | — | -2.6% |
| Shareholder equity | $6.33M | $9.52M | $26.38M | $39.57M | — | -33.5% |
| Working capital | $5.92M | $9.15M | $25.83M | $38.96M | — | -35.3% |
| Net tangible assets | $6.33M | $9.52M | $26.38M | $39.57M | — | -33.5% |
| Shares issued | 13.78M | 10.17M | 10.17M | 8.14M | — | +35.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$8.83M | -$17.50M | -$17.98M | -$38.84M | +49.5% |
| Depreciation & amortisation | $376.00K | $446.00K | -$1.39M | $388.00K | -15.7% |
| Stock-based compensation | $270.00K | $643.00K | $801.00K | $855.00K | -58.0% |
| Change in working capital | $294.00K | $140.00K | $2.34M | -$2.71M | +110.0% |
| Operating cash flow | -$8.19M | -$16.48M | -$14.67M | -$21.43M | +50.3% |
| Capital expenditure | -$12.00K | -$8.00K | -$118.00K | -$74.00K | -50.0% |
| Investing cash flow | -$12.00K | -$8.00K | -$118.00K | -$74.00K | -50.0% |
| Financing cash flow | $5.37M | $0 | $3.99M | -$27.00K | — |
| Free cash flow | -$8.20M | -$16.49M | -$14.78M | -$21.51M | +50.3% |
| End cash position | $7.10M | $9.94M | $26.43M | $37.22M | -28.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $105.00K | $225.00K | $0 | $0 | $0 | — | -53.3% |
| Operating revenue | $105.00K | $225.00K | $0 | $0 | $0 | — | -53.3% |
| Research & development | $2.14M | $1.37M | $1.62M | $954.00K | $1.12M | — | +56.2% |
| Selling, general & admin | $1.15M | $1.21M | $862.00K | $1.14M | $986.00K | — | -5.2% |
| Total operating expense | $3.29M | $2.58M | $2.48M | $2.09M | $2.11M | — | +27.4% |
| Operating income | -$3.18M | -$2.36M | -$2.48M | -$2.09M | -$2.11M | — | -35.1% |
| Net interest income | $10.00K | $22.00K | $47.00K | $22.00K | $28.00K | — | -54.5% |
| Pre-tax income | -$3.16M | -$2.30M | -$2.43M | -$2.05M | -$2.06M | — | -37.6% |
| Net income | -$3.16M | -$2.30M | -$2.43M | -$2.05M | -$2.06M | — | -37.6% |
| Net income to common | -$3.16M | -$2.30M | -$2.43M | -$2.05M | -$2.06M | — | -37.6% |
| Basic EPS | -0.23 | -0.17 | — | -0.19 | -0.20 | -0.23 | -35.3% |
| Diluted EPS | -0.23 | -0.17 | — | -0.19 | -0.20 | -0.23 | -35.3% |
| EBIT | -$3.18M | -$2.36M | -$2.48M | -$2.09M | -$2.11M | — | -35.1% |
| EBITDA | -$3.17M | -$2.34M | -$2.39M | -$1.85M | -$2.09M | — | -35.3% |
| Basic shares | 13.79M | 13.79M | — | 10.99M | 10.17M | 10.17M | +0.0% |
| Diluted shares | 13.79M | 13.79M | — | 10.99M | 10.17M | 10.17M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.17M | $4.68M | $7.03M | $7.73M | $4.77M | -53.7% |
| Cash & short-term investments | $2.17M | $4.68M | $7.03M | $7.73M | $4.77M | -53.7% |
| Total current assets | $3.24M | $5.94M | $8.13M | $8.78M | $6.76M | -45.5% |
| Property, plant & equipment | $1.30M | $1.39M | $1.48M | $1.57M | $1.65M | -6.7% |
| Total assets | $4.65M | $7.43M | $9.71M | $10.45M | $8.51M | -37.4% |
| Total current liabilities | $2.62M | $2.23M | $2.21M | $1.52M | $1.83M | +17.4% |
| Total debt | $1.34M | $1.42M | $1.50M | $1.58M | $1.66M | -5.8% |
| Total liabilities | $3.60M | $3.31M | $3.38M | $2.78M | $3.17M | +8.9% |
| Retained earnings | -$347.71M | -$344.55M | -$342.25M | -$339.82M | -$337.77M | -0.9% |
| Shareholder equity | $1.04M | $4.12M | $6.33M | $7.67M | $5.33M | -74.6% |
| Working capital | $620.00K | $3.71M | $5.92M | $7.26M | $4.93M | -83.3% |
| Net tangible assets | $1.04M | $4.12M | $6.33M | $7.67M | $5.33M | -74.6% |
| Shares issued | 13.79M | 13.79M | 13.78M | 13.04M | 10.17M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$3.16M | -$2.30M | -$2.43M | -$2.05M | -$2.06M | — | -37.6% |
| Depreciation & amortisation | $12.00K | $12.00K | $91.00K | $239.00K | $21.00K | — | 0.0% |
| Stock-based compensation | $92.00K | $84.00K | $56.00K | $48.00K | $84.00K | — | +9.5% |
| Change in working capital | $708.00K | -$137.00K | $621.00K | $475.00K | -$57.00K | — | +616.8% |
| Operating cash flow | -$2.52M | -$2.34M | -$1.74M | -$1.36M | -$2.15M | — | -7.5% |
| Investing cash flow | — | — | $0 | -$12.00K | $0 | $0 | — |
| Financing cash flow | — | — | $1.03M | — | — | — | — |
| Free cash flow | -$2.52M | -$2.34M | -$1.74M | -$1.37M | -$2.15M | — | -7.5% |
| End cash position | $2.24M | $4.76M | $7.10M | $7.80M | $4.84M | — | -52.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.17 | -0.23 | -39.4% |
| Mar 2026 | -0.15 | -0.17 | -13.3% |
| Dec 2025 | -0.18 | -0.17 | +2.9% |
| Sep 2025 | -0.22 | -0.19 | +11.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.14 | 1 | $0 | 0.0% |
| Next quarter | -0.15 | 1 | $0 | 0.0% |
| Current year | -0.69 | 1 | $0 | 0.0% |
| Next year | -0.58 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$9.00
High target$10.00
Low target$8.00
Implied upside710.81%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders65.71%
Held by institutions5.77%
Institutions holding28
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.15
-3.48% from price
SMA 20
1.17
-5.09% from price
SMA 50
1.11
-0.05% from price
SMA 100
1.07
+3.69% from price
SMA 200
1.10
+0.46% from price
EMA 12
1.15
-3.14% from price
EMA 26
1.15
-3.10% from price
EMA 50
1.12
-1.32% from price
RSI (14)
45.1
Neutral
MACD (12,26,9)
0.00
Hist -0.01
ATR (14)
0.07
6.44% of price
Realised vol 30D
51.0%
Annualised
Bollinger upper
1.25
20, 2σ
Bollinger lower
1.09
20, 2σ
50 / 200 cross
Golden
1.11 vs 1.10
Trend bias
Above 200
+0.46%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.58
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
51.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-47.8%
Peak to trough
Max drawdown 5Y
-93.0%
Peak to trough
ATR 14
0.07
6.44% of price
Beta (reported)
1.48
5Y monthly, from filing
Short interest
Shares short
322.75K
Prior 307.61K
Change vs prior
+4.9%
Shorts adding
% of float
2.04%
Normal
% of shares out
1.68%
Against total outstanding
Days to cover
5.7
Crowded exit
Float
11.91M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 22, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 4, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 20, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 3, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 4, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 4, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 11, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 2, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 24, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJan 24, 2018
Last split1:12
Split dateOct 11, 2022
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-09
Corporate Changes & Voting Matters
8-K · 2026-08-18
Corporate Changes & Voting Matters
8-K · 2026-08-17
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-07-17
Corporate Changes & Voting Matters
8-K · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-06-03
Headlines
A norovirus breakthrough?; another women’s healthtech haul
Pharma Voice · 19d ago
Cocrystal Pharma’s new CEO hopes to crack the norovirus code
Pharma Voice · 22d ago
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
GlobeNewswire · 28d ago
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
Exec Edge · 37d ago
COCP: $5 Million Private Placement with OPKO Health
Zacks Small Cap Research · 48d ago
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
GlobeNewswire · 51d ago
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
GlobeNewswire · 65d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.